Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368059 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5497688 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL8176550 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5497444 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL1410606 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL424188 | 0.97 | FDPS (0.38) | GGPS1FDPSSMPD1CES2LPAR1 | |
| SCHEMBL1410618 | 0.90 | — | — | |
| SCHEMBL8906809 | 0.88 | FAAH (0.50) | — | |
| SCHEMBL10530613 | 0.81 | FDPS (0.30) | FDPS | |
| SCHEMBL7722417 | 0.80 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| EP-1204677-B1 | CYCLOHEXAPEPTIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1095947-B1 | NOVEL ANTIBACTERIAL COMPOUNDS | SANKYO CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-6844173-B2 | Strain of Streptomyces griseus | SANKYO COMPANY, LIMITED (JP) | 2005-01-18 | — | — | US | disclosed |
| EP-1319406-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-20030069204-A1 | Strain of streptomyces | SANKYO COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | disclosed |
| US-5854212-A | Cyclohexapeptidyl bisamine compound, compositions containing said compound and methods of use | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0862579-A1 | CYCLOHEXAPEPTIDYL BISAMINE COMPOUND, COMPOSITIONS CONTAINING SAID COMPOUND AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997017365-A1 | CYCLOHEXAPEPTIDYL BISAMINE COMPOUND, COMPOSITIONS CONTAINING SAID COMPOUND AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-05-15 | — | — | WO | disclosed |
| US-5607931-A | AMIDES | SCHERING CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069204-A1 | Strain of streptomyces | O60361, CYP8B1, MRPS34 | GGPS1 147/4885FDPS 415/4885TSHR 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.